A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
HDAC8 inhibition elicits durable responses to immune checkpoint blockade by improving adaptive immune responses through enhancer reprogramming.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most patients, especially patients with HCC, are unresponsive to the blockade of the PD-1/PD-L1 axis5,6.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [6]
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-09234-6 · Cited by 14,611
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · cited 21×
“In this immune-excluded phenotype, T cell migration through the tumor stroma is recognized as the rate-limiting step for ICB therapy, as CD8+ T cells show evidence of activation and proliferation, but not infiltration, upon treatment (1).”
BackgroundInfluentialElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 30×
“In this immune-excluded phenotype, T cell migration through the tumor stroma is recognized as the rate-limiting step for ICB therapy, as CD8+ T cells show evidence of activation and proliferation, but not infiltration, upon treatment (1).”
BackgroundInfluentialGREAT improves functional interpretation of cis-regulatory regions
McLean, C. Y., Bristor, D., Hiller, M., Clarke, S. L., Schaar, B. T., Lowe, C. B., Wenger, A. M., & Bejerano, G. (2010) · Nature Biotechnology · doi:10.1038/nbt.1630 · Cited by 4,502 · cited 2×
“C. Y. McLean, D. Bristor, M. Hiller, S. L. Clarke, B. T. Schaar, C. B. Lowe, A. M. Wenger, G. Bejerano, GREAT improves functional interpretation of cis-regulatory regions.”
BackgroundEl-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Cited by
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer
Wang, X., Fang, Y., Liang, W., Wong, C. C., Qin, H., Gao, Y., Liang, M., Song, L., Zhang, Y., Fan, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.019 · Cited by 247
Self-citationXu, L., Zou, C., Zhang, S., Chu, T. S. M., Zhang, Y., Chen, W., Zhao, C., Yang, L., Xu, Z., Dong, S., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01307-2 · Cited by 209
Self-citation
Metadata
- Authors
- Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., Tan, Z., Sun, H., Tian, Y., Wong, J., Lai, P. B.-S., Chan, S. L., Chan, A. W.-H., Tan, P. B.-O., Chen, Z., Sung, J. J.-Y., Yip, K. Y.-L., To, K.-F., & Cheng, A. S.-L.
- Affiliations
- Chinese University of Hong Kong (HK)
- School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
- University of Hong Kong (HK)
- Shanghai Jiao Tong University (CN)
- Shenzhen University (CN)
- SingHealth (SG)
- Sun Yat-sen University (CN)
- Corresponding author
- Yang, Weiqin
- Feng, Yu
- Zhou, Jingying
- Cheng, Alfred Sze-Lok
- ORCID
- Yang, Weiqin
- Feng, Yu
- Zhou, Jingying
- Cheung, Otto Ka-Wing
- Cao, Jianquan
- Wang, Jing
- Tang, Wenshu
- Tu, Yalin
- Xu, Liangliang
- Wu, Feng
- Tan, Zhiwu
- Tian, Yuan
- Wong, John
- Lai, Paul Bo-San
- Chan, Stephen Lam
- Chan, Anthony Wing-Hung
- Tan, Patrick Boon-Ooi
- Chen, Zhiwei
- Sung, Joseph Jao-Yiu
- Yip, Kevin Yuk-Lap
- To, Ka-Fai
- Cheng, Alfred Sze-Lok
- Venue
- Science Translational Medicine
- Published
- 2021-04-07
- Volume
- 13
- Issue
- 588
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3198872327
- Cited by
- 172
- References
- 72
- Citations by year
- 2026: 30 · 2025: 45 · 2024: 40 · 2023: 23 · 2022: 27 · 2021: 7
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- DR-NTU (Nanyang Technological University) (submittedVersion)
- Funders
- Terry Fox Foundation
- Theme-based Research Scheme (T11-706/18-N)
- University Grants Committee through the Collaborative Research Fund (C4045-18W)
- The Focused Innovations Scheme-Scheme B from the Chinese University of Hong Kong (1907309)
- The Li Ka Shing Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocellular carcinoma, immune checkpoint blockade, PD-L1 blockade, antitumor immunity, memory T cells, enhancer reprogramming, tumor rechallenge, combination therapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Carcinoma, Hepatocellular, Histone Deacetylases, Humans, Liver Neoplasms, Repressor Proteins, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1126/scitranslmed.aaz6804
- The paper
- Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., Tan, Z., Sun, H., Tian, Y., Wong, J., Lai, P. B.-S., Chan, S. L., Chan, A. W.-H., Tan, P. B.-O., Chen, Z., . . . Cheng, A. S.-L. (2021). A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aaz6804
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.